Carmell Therapeutics: Funding, Investors & Team (Oct 2026)
Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).
Carmell Therapeutics has raised $3.0M across 1 funding round on record, the most recent an undisclosed round of $3.0M announced in Apr 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Carmell Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2024.
Carmell Therapeutics Funding Rounds
Carmell Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Carmell Therapeutics Funding Compared to Other Biotechnology Startups
Carmell Therapeutics' latest round of $3.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Carmell Therapeutics in Biotechnology and Pittsburgh
Companies Similar to Carmell Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Carmell Therapeutics Funding FAQs
What does Carmell Therapeutics do?
Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).
How much funding has Carmell Therapeutics raised?
Carmell Therapeutics has raised $3.0M across 1 round on record. The most recent is an undisclosed round of $3.0M announced in Apr 2024.
When did Carmell Therapeutics last raise funding?
Carmell Therapeutics' most recent funding round on record is an undisclosed round of $3.0M, announced in Apr 2024.
Who founded Carmell Therapeutics?
FundedIQ lists James Burgess (Founder) at Carmell Therapeutics.
Where is Carmell Therapeutics headquartered?
Carmell Therapeutics is based in Pittsburgh, Pennsylvania, United States.
How many employees does Carmell Therapeutics have?
Carmell Therapeutics is in the 11-50 employee band.
How does Carmell Therapeutics' funding compare to other Biotechnology startups?
Carmell Therapeutics' latest round of $3.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Carmell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Carmell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.